Psilocybin is a classic psychedelic compound that may have efficacy for the treatment of mood and substance use disorders. Acute psilocybin effects include reduced negative mood, increased positive mood, and reduced amygdala response to negative affective stimuli. However, no study has investigated the long-term, enduring impact of psilocybin on negative affect and associated brain function. Twelve healthy volunteers (7F/5M) completed an open-label pilot study including assessments 1-day before, 1-week after, and 1-month after receiving a 25 mg/70 kg dose of psilocybin to test the hypothesis that psilocybin administration leads to enduring changes in affect and neural correlates of affect. One-week post-psilocybin, negative affect and amygdala response to facial affect stimuli were reduced, whereas positive affect and dorsal lateral prefrontal and medial orbitofrontal cortex responses to emotionally-conflicting stimuli were increased. One-month post-psilocybin, negative affective and amygdala response to facial affect stimuli returned to baseline levels while positive affect remained elevated, and trait anxiety was reduced. Finally, the number of significant resting-state functional connections across the brain increased from baseline to 1-week and 1-month post-psilocybin. These preliminary findings suggest that psilocybin may increase emotional and brain plasticity, and the reported findings support the hypothesis that negative affect may be a therapeutic target for psilocybin. Studies suggest that psilocybin, a classic psychedelic drug (serotonin 2A or 5-HT 2A receptor partial agonist), may have efficacy for the treatment of depression and anxiety 1-3 , tobacco use disorder 4,5 , and alcohol use disorder 6,7. Reduction of clinical symptoms has been shown to last up to 3 3 , 6 1,2 , and 12 8 months after 1 to 3 psilocybin administrations. Despite these promising advances, the neural and psychological mechanisms underlying the enduring therapeutic effects of psychedelic drugs are not well-understood. Two possibly interactive trans-diagnostic targets that may be affected by psilocybin are negative affect and brain network plasticity. Increased negative affect, reduced positive affect, and hypersensitivity to negatively biased information are hallmarks of mood disorders 9-11. Negative affect is also a core component of the cycle of addiction in which craving and withdrawal symptoms experienced after intoxication lead to preoccupation, anticipation, and re-administration of drugs of abuse 12. The amygdala has been shown in clinical and preclinical models to track the salience of stimuli in the environment 13,14 and is highly responsive to negative emotional stimuli 15-17. Abnormally high amygdala reactivity to negative affective stimuli has been implicated in the pathophysiology of depression 18. Areas within the anterior cingulate cortex (ACC) are understood to monitor cognitive conflict 19-22 , are involved in the appraisal and expression of negative emotion 22 , respond to distress levels associated with pain 23 ...